Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06111885 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention

Study acronym: INDAPACHLOR
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Publications: details revised at 1 of 1 entry
    • Collaborators shortened, about 5 words
    v4
  2. Primary and study completion dates: Jun 2027 to Jun 30, 2027
    • Eligibility criteria expanded, about 104 words
    • Collaborator revised
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2024 to Oct 1, 2024
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to test the efficacy of the two long-acting thiazide-like diuretics indapamide and chlorthalidone in reducing urine supersaturation for calcium oxalate and calcium phosphate compared to the short-acting thiazide diuretic hydrochlorothiazide for the prevention of calcium-containing kidney stones.
Trial Details
NCT Number NCT06111885
Lead Sponsor Insel Gruppe AG, University Hospital Bern
Conditions
(from sponsor)		 Kidney Stone
Related terms Kidney Calculi, Nephrolithiasis
Enrollment 99 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov